ReCode Therapeutics
1455 Adams Drive, Suite 1120
Menlo Park, CA 94025
United States
Tel: 408-585-1700
Website: https://recodetx.com/
Email: info@recodetx.com
About ReCode Therapeutics
We are an integrated genetic medicines company developing targeted, disease-modifying medicines for patients with life-limiting respiratory diseases. Our treatments address the underlying genetic cause in underserved populations and have the potential to tremendously impact the quality and length of patients’ lives. We have created a broad and customizable platform of non-viral lipid nanoparticles (LNPs), enabling us to precisely deliver our medicines safely and effectively.
With our SORT LNP delivery platform, we can hone in on previously inaccessible targets by delivering the payload precisely to a specific organ. Our proprietary delivery platforms can be customized to treat different respiratory diseases and targeted organs. Our ability to carry different types of cargo (mRNA, tRNA, CRISPR) with multiple delivery systems allows us to advance several drug candidates simultaneously. Ultimately, we match the best delivery approach to the specific problem, providing incredible flexibility in how we can potentially treat patients.
By harnessing our deep experience with well-defined drug development and regulatory pathways, we will rapidly advance our lead programs for cystic fibrosis (CF) caused by nonsense mutations and primary ciliary dyskinesia (PCD) – ultimately having a significant effect where there is a clear, unmet, and high-hurdle need.
11 articles with ReCode Therapeutics
-
ReCode Therapeutics to Present Preclinical Data from mRNA-Based Program for Primary Ciliary Dyskinesia at the 2021 PCD on the Move Virtual Scientific Conference
7/30/2021
ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced preclinical data from the Company’s inhaled mRNA-based molecular therapy program for primary ciliary dyskinesia will be presented in an oral and poster presentation at the 2021 PCD on the Move Virtual Scientific Conference,
-
ReCode Therapeutics to Present at William Blair Biotech Focus Conference 2021
7/8/2021
ReCode Therapeutics today announced that CEO and President, David Lockhart, Ph.D., will participate in a panel discussion on non-viral drug delivery at the upcoming William Blair Biotech Focus Conference 2021 at 2:00 pm Eastern Time on Thursday, July 15, 2021.
-
Vida Ventures III will approach investments the same way its first two funds do, identifying and investing in what they believe to be transformative biomedical innovative companies.
-
The data showed that both experimental therapies restored function in the cystic fibrosis transmembrane conductance regulator gene.
-
ReCode Therapeutics to Participate in Upcoming June Investor Conferences
6/14/2021
ReCode Therapeutics today announced that the Company will participate in two upcoming virtual investor conferences in June.
-
ReCode Therapeutics Presents Preclinical Data Using SORT-LNP™ and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS)
6/11/2021
ReCode Therapeutics Presents Preclinical Data Using SORT-LNP ™ and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS).
-
ReCode Therapeutics to Present Preclinical Data Using SORT-LNP™ and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS)
5/24/2021
ReCode Therapeutics to Present Preclinical Data Using SORT-LNP ™ and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS)
-
ReCode Therapeutics to Participate in Upcoming Investor Conferences - Feb 16, 2021
2/16/2021
ReCode Therapeutics™, a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, announced that members of the executive team will be participating in three upcoming virtual investor conferences.
-
ReCode Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
1/11/2021
ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced that David Lockhart, CEO, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:30 p.m. ET on Wednesday, January 13, 2021.
-
ReCode Therapeutics Appoints Julie Eastland as Chief Operating Officer and Chief Financial Officer
10/13/2020
ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced the appointment of Julie Eastland as chief operating officer (COO) and chief financial officer (CFO
-
ReCode Therapeutics Strengthens Leadership Team With New Appointments
9/9/2020
- Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC - Brandon Wustman, Ph.D. promoted to Senior Vice President, R&D MENLO PARK, Calif. & DALLAS--( BUSINESS WIRE )-- ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering precision medicines for life-limiting respiratory diseases, today announced two key executive appointments. Mu